NCT01523418View on ClinicalTrials.gov

Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)

WithdrawnOBSERVATIONAL

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Prophylaxis, Thromboembolism, VenousTotal Knee ReplacementTotal Hip Replacement

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)